Cargando…

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Ailawadhi, Sikander, Panjabi, Sumeet, Campioni, Marco, Majer, Istvan, Jakubowiak, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397654/ https://www.ncbi.nlm.nih.gov/pubmed/29952705 http://dx.doi.org/10.18553/jmcp.2018.24.7.711

Ejemplares similares

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
por: MacEwan, Joanna P, et al.
Publicado: (2021)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma
por: Orlowski, Robert Z.
Publicado: (2018)

P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY
por: Popat, Rakesh, et al.
Publicado: (2023)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study
por: Biran, Noa, et al.
Publicado: (2020)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021)

Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
por: Rodriguez, Cesar, et al.
Publicado: (2023)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
por: Cerchione, Claudio, et al.
Publicado: (2016)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis
por: Song, Xue, et al.
Publicado: (2019)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ia6vb4ia10gr0eeud4opep141